ATOS Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 06, 2023|
Current P/E* ratio: -3.11 | Price (Sep 29, 2023, EOD): $0.737
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for ATOS Premium
About Atossa Genetics Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien... ATOS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.